Join a Research Study
The COMP006 Study
Exploring Potential New Routes Away From Treatment-Resistant Depression
Many people who receive antidepressant treatment for their depression do not get an adequate response to the medicines they are taking. If someone is taking two or more antidepressants and they are failing, this is sometimes referred to as treatment-resistant depression or TRD.
Introducing the COMP006 Study
The COMP 006 study is looking into a new treatment approach for people with TRD using an investigational medicine given with psychological support. The study is suitable for people who have been diagnosed with major depression and are currently experiencing a recurrent or single episode of depression but that have not responded to antidepressant treatment.
Eligibility
- You may be eligible to participate in a Compass Pathfinder study if you:
- Are 18 years of age or older
- Have been diagnosed with major depression (single or recurrent episodes)
- Are experiencing treatment-resistant depression, defined as failing 2, 3 or 4 pharmacological treatments for your current episode of depression
- Meet additional study criteria.
About the Study
COMP006 is a three-part study which will last up to 62 weeks.
Participants will receive support from study clinicians to help them withdraw off any prohibited medications, including current antidepressants. Participants will be asked to remain off prohibited medications for parts of the study under close medical supervision.
Reimbursement for reasonable, out-of-pocket expenses for travel and other expenses may be available to qualified individuals.
More Information
If you are interested in learning more about the COMP006 study, please contact us for an informal chat at:
E-mail: contact@gminstitutes.com – Call: 609-921-6050 – Text: 609-921-3555.
We will ask you some brief questions and provide additional information about the study.
Expressing an interest does not oblige you in any way to take part in the study. So please, do get in touch if you want to find out more.
